Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for EGFR Exon 20 Insertion Mutation NSCLC
NCT05668988Phase 3Active, not recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Dec 2022
- Primary completion
- Jan 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 15
01
Overview
Phase 3, randomised, open-label trial of sunvozertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoint: Progression Free Survival at 34 months. Started Dec 2022; status: active, not recruiting.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05668988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05668988.